Results
1 -
10 of
79Second-Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status, Renal Cell Carcinoma Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles, Archives of Toxicology The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis, Naunyn-Schmiedeberg's Archives of Pharmacology Ist Pazopanib eine neue Option?, Info Onkologie Tyrosinkinaseinhibition beim metastasierten RCC, Uro-News A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology Phase I study of pazopanib plus TH-302 in advanced solid tumors, Cancer Chemotherapy and Pharmacology A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors, Cancer Chemotherapy and Pharmacology